Cited by 555Long-Term Effects of COVID-19COVID-19 Clinical Research StudiesInfectious Encephalopathies and Encephalitis

Immediate and long-term consequences of COVID-19 infections for the development of neurological disease

Open access
Heneka, Michael T., Golenbock, Douglas, Latz, Eicke, Morgan, Dave, Brown, Robert·2020·Alzheimer's Research & Therapy

Abstract

Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, less is known about the possible long-term consequences for the brain. Severely affected COVID-19 cases experience high levels of proinflammatory cytokines and acute respiratory dysfunction and often require assisted ventilation. All these factors have been suggested to cause cognitive decline. Pathogenetically, this may result from direct negative effects of the immune reaction, acceleration or aggravation of pre-existing cognitive deficits, or de novo induction of a neurodegenerative disease. This article summarizes the current understanding of neurological symptoms of COVID-19 and hypothesizes that affected patients may be at higher risk of developing cognitive decline after overcoming the primary COVID-19 infection. A structured prospective evaluation should analyze the likelihood, time course, and severity of cognitive impairment following the COVID-19 pandemic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-020-00640-3

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Anti-inflammatory effects of guanfacine may be useful for treating long-term neural consequences of COVID-19.

    “The anti-inflammatory effects of guanfacine may also be useful for treating the long-term neural consequences of COVID-19”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Heneka et al., 2020

    The Main text (page unavailable) links systemic inflammation in COVID-19 to possible long-term cognitive decline and neurodegeneration. It does not mention guanfacine, establish its anti-inflammatory effects, or suggest that it could treat those consequences. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • A subset of COVID-19 patients report sustained mental problems.

    “where a subset of patients report sustained mental problems (Heneka et al., 2020, Pinna et al., 2020)”

    From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Heneka et al., 2020

    The Main text reports evidence of cognitive impairment in one third of patients at discharge, supporting the claim that a subset had cognitive problems. But it describes long-term consequences as a risk requiring prospective study, not as sustained mental problems that patients had reported. No page numbers are provided in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Heneka, M. T., Golenbock, D., Latz, E., Morgan, D., & Brown, R.
Affiliations
  • University of Bonn (DE)
  • German Center for Neurodegenerative Diseases (DE)
  • University of Massachusetts Chan Medical School (US)
Corresponding author
Heneka, Michael T.
Venue
Alzheimer's Research & Therapy
Published
2020-06-04
Volume
12
Issue
1
Pages
69-69
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3032981909
Cited by
555
References
27
Citations by year
2026: 18 · 2025: 36 · 2024: 74 · 2023: 72 · 2022: 165 · 2021: 137 · 2020: 52 · 2013: 1
FWCI
46.12
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion, cc-by)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DZNE Pub (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • National Institute on Aging (R01AG059752)
Topics
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
Keywords
COVID-19 pandemic, SARS-CoV-2, neurological complications, cognitive decline, long-term effects, neuroinflammation, inflammatory cytokines, neurodegenerative diseases, post-COVID cognitive impairment, mechanical ventilation
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Animals, Brain, Humans, Pneumonia, Viral, Time Factors, Coronavirus Infections, Neurodegenerative Diseases, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review